Quick infos Headquarters: Copenhagen, Denmark Trade prices Volume: Market Cap: 21.88B Prev closed: Open: 42.8 High: 43.24 Low: 42.68 52 week low: 30.1 52 week high: 49.07 Dividends: No Dividends Next ER: August 9, 2023 Before Market Opens
About the Company Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. Genmab is based in Copenhagen.
Earnings History Date EPS / Forecast Revenue / Forecast November 7, 2023 August 3, 2023 20.61 / 19.694.2B / 4.07BBeat! May 10, 2023 3.43 / 6.482.85B / 2.79BBeat! February 22, 2023 8.77 / 23.635.23B / 4.72BBeat! November 9, 2022 39.17 / 16.484.09B / 3.57BBeat! view more
Historical Data Date Price Open High Low Vol Change ER May 15, 2023 42 41.85 42.01
41.83
13.8K 0.74% May 12, 2023 41.69 41.43 42.01
41.43
358K -0.64% May 11, 2023 41.96 42.09 42.19
41.74
708K 3.99% May 10, 2023 40.35 39.64 40.48
39.59
529K 1.95% May 9, 2023 39.58 39.46 39.79
39.42
268K -1.96% May 8, 2023 40.37 40.43 40.6
40.23
335K 0% May 5, 2023 40.37 40.24 40.47
39.91
376K 0.32% May 4, 2023 40.24 40.51 40.51
40.13
385K -1.73% May 3, 2023 40.95 40.75 41.52
40.66
330K 0.15% May 2, 2023 40.89 40.72 41.02
40.66
324K 0.07% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company Founded:1999 Employees:157 (2013) News
Genmab downgraded to hold at Deutsche Bank on candidate data at upcoming conferences seekingalpha.com Nov 12, 2022 4:12 am Genmab A/S GAAP EPS of DKK39.17, revenue of DKK4.09B seekingalpha.com Nov 10, 2022 12:54 am Genmab A/S Q3 2022 Earnings Preview seekingalpha.com Nov 9, 2022 2:07 am
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) finance.yahoo.com Sep 29, 2022 5:26 pm
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab finance.yahoo.com Sep 29, 2022 4:13 pm
Genmab Announces Financial Results for the First Half of 2022 finance.yahoo.com Sep 29, 2022 11:01 am Genmab ups 2022 revenue guidance on positive FX impact, strong Darzalex sales seekingalpha.com Nov 4, 2022 6:36 am Genmab files for approval of blood cancer drug in US, AbbVie gets review in EU seekingalpha.com Oct 28, 2022 9:29 pm Genmab reports Q3 worldwide sales of $2.05B for Darzalex seekingalpha.com Oct 18, 2022 6:48 pm
Genmab Publishes 2021 Annual Report finance.yahoo.com Sep 29, 2022 11:00 am
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting finance.yahoo.com Sep 29, 2022 11:00 am
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma finance.yahoo.com Sep 29, 2022 10:00 am
Passing of Genmab A/S Annual General Meeting finance.yahoo.com Sep 29, 2022 9:15 am
Transactions in connection with share buy-back program finance.yahoo.com Sep 29, 2022 7:27 am
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates finance.yahoo.com Sep 29, 2022 6:45 am
AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study finance.yahoo.com Sep 29, 2022 6:09 am
Transactions in connection with share buy-back program finance.yahoo.com Sep 29, 2022 5:50 am
Transactions in connection with share buy-back program finance.yahoo.com Sep 29, 2022 4:50 am
Transactions in connection with share buy-back program finance.yahoo.com Sep 29, 2022 4:18 am Seagen partners with Zai Lab to introduce cervical cancer drug in China seekingalpha.com Sep 27, 2022 8:26 pm This company doesn't provide a dividend.
Key Persons CEO : Jan G. J. van de Winkel (15 Jun 2010–) CFO : Anthony Pagano Talk about Genmab below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon Graham's philosophy of "value investing" has made The Intelligent Investor the stock market bible ever since its original publication in 1949.
The best book on investing ever written. -- Warren Buffet